Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Babim

Drug Profile

Babim

Latest Information Update: 10 Dec 1998

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of North Carolina
  • Developer Celera Genomics Group; University of North Carolina
  • Class Antirheumatics; Antivirals
  • Mechanism of Action Trypsin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatic disorders; Viral infections

Most Recent Events

  • 10 Dec 1998 Discontinued-Preclinical for Rheumatic disorders in USA (Unknown route)
  • 10 Dec 1998 Discontinued-Preclinical for Viral infections in USA (Unknown route)
  • 06 Apr 1998 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top